INDUSTRY NEWS
Arthur Cummings
Published: Tuesday, March 3, 2015
Nicox S.A. has announced the signature of a licence agreement with InSite Vision Inc. for the development, manufacture and commercialisation of InSite’s innovative ophthalmic therapeutics AzaSite® (one per cent azithromycin), BromSiteTM (0.075 per cent bromfenac) and AzaSite XtraTM (two per cent azithromycin).
All three products are based on InSite’s proprietary Durasite® drug delivery technology, which is designed to extend the duration of a drug in the eye. The agreement grants Nicox exclusive rights to all three products in Europe, Middle East and Africa. European Marketing Authorisation Applications (MAAs) for AzaSite® and BromSiteTM are expected to be filed by Q1 2016.
www.nicox.com
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.